Effect of ezetimibe on insulin secretion in db/db diabetic mice

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Zhong, Yong ^a   Wang, Jun ^a   Gu, Ping ^a   Shao, Jiaqing ^a   Lu, Bin ^a   Jiang, Shisen ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EZETIMIBE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ANTIDIABETIC AGENT; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET; PANCREAS PERFUSION; PRIORITY JOURNAL; ANIMAL; BLOOD; CONGENIC STRAIN; DRUG EFFECT; GERMFREE ANIMAL; GLUCOSE INTOLERANCE; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; KINETICS; METABOLISM; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOLOGY; RANDOMIZATION; SECRETION (PROCESS);

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; KINETICS; MALE; MICE; MICE, CONGENIC; MICE, MUTANT STRAINS; RANDOM ALLOCATION; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84869034578     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/420854     Document Type: Article

References (15)

1. Preiss D., Seshasai S. R. K., Welsh P., Murphy S. A., Ho J. E., Waters D. D., DeMicco D. A., Barter P., Cannon C. P., Sabatine M. S., Braunwald E., Kastelein J. J. P., de Lemos J. A., Blazing M. A., Pedersen T. R., Tikkanen M. J., Sattar N., Ray K. K., Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. The Journal of the American Medical Association 2011 305 24 2556 2564 2-s2.0-79959428660 10.1001/jama.2011.860
2. Simsek S., Schalkwijk C. G., Wolffenbuttel B. H. R., Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetesthe CORALL study. Diabetic Medicine 2012 29 5 628 631 2-s2.0-84859847419 10.1111/j.1464-5491.2011.03553.x
3. Okada K., Yagyu H., Kotani K., Miyamoto M., Osuga J. I., Nagasaka S., Ishibashi S., Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus. Endocrine Journal 2010 57 10 903 908 2-s2.0-78649386408 10.1507/endocrj.K10E-055
4. Deushi M., Nomura M., Kawakami A., Haraguchi M., Ito M., Okazaki M., Ishii H., Yoshida M., Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Letters 2007 581 29 5664 5670 2-s2.0-36549013633 10.1016/j.febslet.2007.11.023 (Pubitemid 350179776)
5. Suchy D., abuzek K., Stadnicki A., Okopie B., Ezetimibea new approach in hypercholesterolemia management. Pharmacological Reports 2011 63 6 1335 1348 2-s2.0-84857490179
6. Altmann S. W., Davis H. R. Jr., Zhu L. J., Yao X., Hoos L. M., Tetzloff G., Iyer S. P. N., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., Graziano M. P., Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004 303 5661 1201 1204 2-s2.0-10744221008 10.1126/science.1093131 (Pubitemid 38233587)
7. Chan D. C., Watts G. F., Gan S. K., Ooi E. M. M., Barrett P. H. R., Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010 33 5 1134 1139 2-s2.0-77952674608 10.2337/dc09-1765
8. Nomura M., Ishii H., Kawakami A., Yoshida M., Inhibition of hepatic Niemann-pick C1-like 1 improves hepatic insulin resistance. American Journal of Physiology 2009 297 5 E1030 E1038 2-s2.0-70350468701 10.1152/ajpendo.00343.2009
9. Shao J. Q., Gu P., DU H., Lu B., Peng L., Li J., Wang Y. Y., Zhao M., Wang J., Islet perifusion: a new method to evaluate first-phase insulin secretory function of β -cell in vitro. Zhonghua Yi Xue Za Zhi 2010 90 2 119 122 2-s2.0-77953268875
10. Naples M., Baker C., Lino M., Iqbal J., Hussain M. M., Adeli K., Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. American Journal of Physiology 2012 302 9 G1043 G1052 2-s2.0-84860504570 10.1152/ajpgi.00250.2011
11. Hiramitsu S., Ishiguro Y., Matsuyama H., Yamada K., Kato K., Noba M., Uemura A., Yoshida S., Matsubara Y., Kani A., Hasegawa K., Hishida H., Ozaki Y., The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. Journal of Atherosclerosis and Thrombosis 2010 17 1 106 114 2-s2.0-76249107102
12. Russell M., Silverman A., Fleg J. L., Lee E. T., Mete M., Weir M., Wilson C., Yeh F., Howard B. V., Howard W. J., Achieving lipid targets in adults with type 2 diabetes: the stop atherosclerosis in native diabetics study. Journal of Clinical Lipidology 2010 4 5 435 443 2-s2.0-77957871238 10.1016/j.jacl.2010.07. 007
13. Yang S. J., Choi J. M., Kim L., Kim B. J., Sohn J. H., Kim W. J., Park S. E., Rhee E. J., Lee W. Y., Oh K. W., Park S. W., Kim S. W., Park C. Y., Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes. Biochemical and Biophysical Research Communications 2011 407 1 153 157 2-s2.0-79953163093 10.1016/j.bbrc.2011.02.129
14. Bajaj M., Suraamornkul S., Kashyap S., Cusi K., Mandarino L., DeFronzo R. A., Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2004 89 9 4649 4655 2-s2.0-4544302447 10.1210/jc.2004-0224 (Pubitemid 39244483)
15. Kikuchi K., Nezu U., Inazumi K., Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. Journal of Atherosclerosis and Thrombosis. In press 10.5551/jat.12427